CL2015000544A1 - Una composicion farmaceutica que comprende regorafenib y al menos un excipiente farmaceuticamente aceptable, en el que la composicion esta recubierta por un recubrimiento que comprende un polimero basado en alcohol polivinilico; y su procedimiento de preparacion. - Google Patents
Una composicion farmaceutica que comprende regorafenib y al menos un excipiente farmaceuticamente aceptable, en el que la composicion esta recubierta por un recubrimiento que comprende un polimero basado en alcohol polivinilico; y su procedimiento de preparacion.Info
- Publication number
- CL2015000544A1 CL2015000544A1 CL2015000544A CL2015000544A CL2015000544A1 CL 2015000544 A1 CL2015000544 A1 CL 2015000544A1 CL 2015000544 A CL2015000544 A CL 2015000544A CL 2015000544 A CL2015000544 A CL 2015000544A CL 2015000544 A1 CL2015000544 A1 CL 2015000544A1
- Authority
- CL
- Chile
- Prior art keywords
- composition
- regorafenib
- coated
- coating
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12183331 | 2012-09-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015000544A1 true CL2015000544A1 (es) | 2015-08-21 |
Family
ID=46963450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015000544A CL2015000544A1 (es) | 2012-09-06 | 2015-03-05 | Una composicion farmaceutica que comprende regorafenib y al menos un excipiente farmaceuticamente aceptable, en el que la composicion esta recubierta por un recubrimiento que comprende un polimero basado en alcohol polivinilico; y su procedimiento de preparacion. |
Country Status (43)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| EP3043778B1 (en) * | 2013-09-13 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Pharmaceutical compositions containing refametinib |
| CN104586808B (zh) * | 2014-12-27 | 2017-08-18 | 北京元延医药科技股份有限公司 | 抗肿瘤药物组合物 |
| CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
| CN105136956A (zh) * | 2015-09-11 | 2015-12-09 | 江苏嘉逸医药有限公司 | 一种快速测定瑞戈非尼含量的方法 |
| CN106880615A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种瑞戈非尼的口服固体制剂及其制备方法 |
| CN106880607A (zh) * | 2015-12-15 | 2017-06-23 | 北大方正集团有限公司 | 一种含有瑞戈非尼的口腔崩解片及其制备方法 |
| CN105496975B (zh) * | 2015-12-17 | 2019-01-04 | 河南润弘制药股份有限公司 | 一种瑞戈非尼片剂及其制备方法 |
| CN106913527A (zh) * | 2015-12-28 | 2017-07-04 | 江苏先声药业有限公司 | 一种瑞戈非尼速释微丸及其制备方法 |
| CN105879049B (zh) * | 2016-05-13 | 2019-03-26 | 浙江大学 | 一种瑞戈非尼与β-环糊精的包合物及其制备方法 |
| CN107661296A (zh) * | 2016-07-27 | 2018-02-06 | 江苏先声药业有限公司 | 一种瑞戈非尼固体分散体及其制备方法 |
| PT3630112T (pt) * | 2017-06-02 | 2024-04-23 | Bayer Healthcare Llc | Combinação de regorafenib e nivolumab para tratamento de cancro |
| CA3103498A1 (en) * | 2018-07-06 | 2020-01-09 | Agios Pharmaceuticals, Inc. | Ivosidenib forms and pharmaceutical compositions |
| CN111053751A (zh) * | 2018-10-16 | 2020-04-24 | 正大天晴药业集团股份有限公司 | 瑞戈非尼的缓释片剂及其制备方法 |
| TWI799599B (zh) * | 2019-06-06 | 2023-04-21 | 華納國際生物科技股份有限公司 | 醫藥或保健品自乳化固體分散組成物 |
| EP3861989A1 (en) * | 2020-02-07 | 2021-08-11 | Bayer Aktiengesellschaft | Pharmaceutical composition containing regorafenib and a stabilizing agent |
| CN112587485A (zh) * | 2021-01-08 | 2021-04-02 | 湖南南新制药股份有限公司 | 一种药物固体分散体及其制备方法 |
| CN113018274A (zh) * | 2021-03-10 | 2021-06-25 | 药源生物科技（启东）有限公司 | 一种含羟丙甲纤维素的药物组合物及其制备方法 |
| TR2023002707A2 (tr) * | 2023-03-10 | 2024-09-23 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Regorafenib içeren bir farmasötik bileşim. |
| WO2025242583A1 (en) | 2024-05-24 | 2025-11-27 | Bayer Consumer Care Ag | Novel formulation comprising elinzanetant in a solid dispersion |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2529180T3 (es) * | 2002-09-20 | 2015-02-17 | Andrx Labs Llc | Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona |
| CN1265793C (zh) * | 2002-11-18 | 2006-07-26 | 杭州容立医药科技有限公司 | 左西替利嗪伪麻黄碱复方口服制剂及制备方法 |
| PL1663978T3 (pl) * | 2003-07-23 | 2008-04-30 | Bayer Healthcare Llc | Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| JP2009519266A (ja) * | 2005-12-15 | 2009-05-14 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 炎症性の皮膚、眼および／または耳疾患を処置するためのジアリールウレア類 |
| AR062927A1 (es) * | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| WO2008044111A1 (en) * | 2006-10-13 | 2008-04-17 | Pfizer Products Inc. | Pharmaceutical formulation tablet |
| AU2007333302A1 (en) * | 2006-12-07 | 2008-06-19 | Eli Lilly And Company | An article comprising prasugrel |
| JP5351490B2 (ja) * | 2007-10-25 | 2013-11-27 | バイエル薬品株式会社 | ニフェジピン含有有核錠剤およびその製法 |
| AR081060A1 (es) * | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| ES2643693T3 (es) * | 2011-05-20 | 2017-11-23 | Astrazeneca Uk Limited | Composición farmacéutica de rosuvastatina cálcica |
-
2013
- 2013-09-04 JO JOP/2013/0268A patent/JO3479B1/ar active
- 2013-09-04 AR ARP130103145A patent/AR092439A1/es not_active Application Discontinuation
- 2013-09-04 UY UY0001035006A patent/UY35006A/es active IP Right Grant
- 2013-09-05 PL PL13762967T patent/PL2892507T3/pl unknown
- 2013-09-05 IN IN1673DEN2015 patent/IN2015DN01673A/en unknown
- 2013-09-05 HK HK16102327.2A patent/HK1214170A1/zh unknown
- 2013-09-05 PE PE2015000289A patent/PE20151005A1/es active IP Right Grant
- 2013-09-05 JP JP2015531194A patent/JP6445436B2/ja active Active
- 2013-09-05 EA EA201590520A patent/EA027685B1/ru not_active IP Right Cessation
- 2013-09-05 CN CN202310409897.2A patent/CN116392484A/zh active Pending
- 2013-09-05 KR KR1020157008402A patent/KR102162036B1/ko active Active
- 2013-09-05 HR HRP20170620TT patent/HRP20170620T1/hr unknown
- 2013-09-05 MY MYPI2015700672A patent/MY176135A/en unknown
- 2013-09-05 UA UAA201502818A patent/UA115994C2/uk unknown
- 2013-09-05 ES ES13762967.1T patent/ES2623205T3/es active Active
- 2013-09-05 PT PT137629671T patent/PT2892507T/pt unknown
- 2013-09-05 HU HUE13762967A patent/HUE032758T2/en unknown
- 2013-09-05 CN CN201380049461.1A patent/CN104902878A/zh active Pending
- 2013-09-05 AP AP2015008292A patent/AP2015008292A0/xx unknown
- 2013-09-05 DK DK13762967.1T patent/DK2892507T3/en active
- 2013-09-05 NZ NZ705578A patent/NZ705578A/en unknown
- 2013-09-05 CU CUP2015000020A patent/CU24244B1/es unknown
- 2013-09-05 AU AU2013312531A patent/AU2013312531B2/en active Active
- 2013-09-05 SG SG11201501683WA patent/SG11201501683WA/en unknown
- 2013-09-05 CN CN202010052300.XA patent/CN111249247A/zh active Pending
- 2013-09-05 WO PCT/US2013/058257 patent/WO2014039677A1/en not_active Ceased
- 2013-09-05 LT LTEP13762967.1T patent/LT2892507T/lt unknown
- 2013-09-05 CN CN202310406916.6A patent/CN116392598A/zh active Pending
- 2013-09-05 CA CA2883767A patent/CA2883767C/en active Active
- 2013-09-05 MA MA37888A patent/MA37888B1/fr unknown
- 2013-09-05 SI SI201330621T patent/SI2892507T1/sl unknown
- 2013-09-05 EP EP13762967.1A patent/EP2892507B1/en active Active
- 2013-09-05 US US14/018,516 patent/US20140065212A1/en not_active Abandoned
- 2013-09-05 BR BR112015004936-2A patent/BR112015004936B1/pt not_active IP Right Cessation
- 2013-09-05 MX MX2015002815A patent/MX359922B/es active IP Right Grant
- 2013-09-05 CN CN202310410047.4A patent/CN116392485A/zh active Pending
- 2013-09-05 EP EP17153541.2A patent/EP3243508A1/en not_active Withdrawn
- 2013-09-05 TW TW102131928A patent/TWI640329B/zh active
- 2013-09-05 RS RS20170400A patent/RS56019B1/sr unknown
-
2015
- 2015-02-22 IL IL237350A patent/IL237350B/en active IP Right Grant
- 2015-03-02 ZA ZA2015/01394A patent/ZA201501394B/en unknown
- 2015-03-03 PH PH12015500460A patent/PH12015500460A1/en unknown
- 2015-03-04 SA SA515360113A patent/SA515360113B1/ar unknown
- 2015-03-05 CL CL2015000544A patent/CL2015000544A1/es unknown
- 2015-03-05 CR CR20150114A patent/CR20150114A/es unknown
- 2015-03-05 GT GT201500053A patent/GT201500053A/es unknown
- 2015-03-05 CO CO15050805A patent/CO7310528A2/es unknown
-
2017
- 2017-04-21 CY CY20171100450T patent/CY1118839T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013002504A1 (es) | Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion | |
| NI201200074A (es) | Composición farmacéutica que comprende un agonista de glp-1, una insulina y metionina. | |
| ECSP12012148A (es) | Composiciones sólidas | |
| CL2013001942A1 (es) | Composicion de suministro de farmaco biodegradable que comprende a) un copolimero de tres bloques biodegradable, b) un copolimero de dos bloques biodegradable, y c) cuando menos un principio farmaceuticamente activo; metodo para su preparacion: y su uso. | |
| IT1400982B1 (it) | Collirio osmotico trans-epiteliale per la cura del cheratocono. | |
| WO2011120904A3 (en) | A fast dissolving pharmaceutical composition | |
| CL2011002968A1 (es) | Forma de dosificacion de extrusion por fusion caliente de un ingrediente activo (a) incluido en una matriz que comprende un polimero (c), que el nucleo presenta una orientacion morfologica ortogonal respecto a la direccion longitudinal de extension de la forma de dosificacion; y su procedimiento de preparacion. | |
| CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
| CL2014003171A1 (es) | Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica. | |
| BRPI0919796A2 (pt) | formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitável | |
| BRPI1010617A2 (pt) | uso de uma composição, composição, uso não médico da composição, e, método para preprar uma composição. | |
| EP3056538A4 (en) | Saponified ethylene-vinyl ester copolymer composition, and multilayer structure using said composition | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| CL2013001979A1 (es) | Composicion farmaceutica en tableta, que comprende compuestos inmunosupresores, moduladores del receptor s1p, que incluye tambien un desecante y se recubre con una barrera a la humedad. | |
| BR112014025041B8 (pt) | Composição farmacêutica | |
| CO2017006898A2 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| WO2011120903A3 (en) | A fast dissolving pharmaceutical composition | |
| BR112014020992A2 (pt) | Composto,uso de composto na fabricação de um medicamento e composição farmacêutica | |
| BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. | |
| WO2013106068A3 (en) | Therapeutic compositions of specified herbal formulations and uses thereof | |
| CL2013002905A1 (es) | Composición farmacéutica que comprende fimasartan, una sal, solvato o hidrato del mismo y amlodipina, un isómero, sal, solvato o hidrato del mismo; uso en el tratamiento de hipertensión y enfermedades cardiovasculares. | |
| BRPI0915527A2 (pt) | pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos | |
| CL2013003700A1 (es) | Composicion farmaceutica oftalmologica topica que comprende regorafenib, el cual se encuentra suspendido en un vehiculo farmaceuticamente aceptable; procedimiento de fabricacion y su uso para tratar o prevenir un trastorno oftalmologico. | |
| PH12015500165A1 (en) | Formulations and methods of manufacturing formulations for use in colonic evacuation | |
| BR112012028533A8 (pt) | cateter e seu uso, método para iniciar pleurodese e método para irritar ou enrugar uma superfície |